JP2016512525A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016512525A5 JP2016512525A5 JP2016501297A JP2016501297A JP2016512525A5 JP 2016512525 A5 JP2016512525 A5 JP 2016512525A5 JP 2016501297 A JP2016501297 A JP 2016501297A JP 2016501297 A JP2016501297 A JP 2016501297A JP 2016512525 A5 JP2016512525 A5 JP 2016512525A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- chain variable
- region
- represented
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims description 49
- 239000000427 antigen Substances 0.000 claims description 45
- 102000036639 antigens Human genes 0.000 claims description 45
- 108091007433 antigens Proteins 0.000 claims description 45
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 40
- 102000014128 RANK Ligand Human genes 0.000 claims description 16
- 108010025832 RANK Ligand Proteins 0.000 claims description 16
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 8
- 238000006467 substitution reaction Methods 0.000 claims description 6
- 206010065687 Bone loss Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 102000040430 polynucleotide Human genes 0.000 claims description 4
- 108091033319 polynucleotide Proteins 0.000 claims description 4
- 239000002157 polynucleotide Substances 0.000 claims description 4
- 241000282414 Homo sapiens Species 0.000 claims description 3
- 101000830603 Homo sapiens Tumor necrosis factor ligand superfamily member 11 Proteins 0.000 claims description 3
- 102000053529 human TNFSF11 Human genes 0.000 claims description 3
- 208000002966 Giant Cell Tumor of Bone Diseases 0.000 claims description 2
- 208000017670 Juvenile Paget disease Diseases 0.000 claims description 2
- 206010027476 Metastases Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 208000010191 Osteitis Deformans Diseases 0.000 claims description 2
- 208000003076 Osteolysis Diseases 0.000 claims description 2
- 208000001132 Osteoporosis Diseases 0.000 claims description 2
- 208000027868 Paget disease Diseases 0.000 claims description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 201000002797 childhood leukemia Diseases 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 239000013604 expression vector Substances 0.000 claims description 2
- 208000029791 lytic metastatic bone lesion Diseases 0.000 claims description 2
- 208000027202 mammary Paget disease Diseases 0.000 claims description 2
- 230000009401 metastasis Effects 0.000 claims description 2
- 201000001245 periodontitis Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 239000013598 vector Substances 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 2
- 210000002997 osteoclast Anatomy 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361786050P | 2013-03-14 | 2013-03-14 | |
| US61/786,050 | 2013-03-14 | ||
| PCT/US2014/023623 WO2014159430A1 (en) | 2013-03-14 | 2014-03-11 | Anti-rankl antibodies and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018142624A Division JP2018183176A (ja) | 2013-03-14 | 2018-07-30 | 抗rankl抗体および使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016512525A JP2016512525A (ja) | 2016-04-28 |
| JP2016512525A5 true JP2016512525A5 (enExample) | 2017-04-13 |
| JP6525432B2 JP6525432B2 (ja) | 2019-06-05 |
Family
ID=51625166
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016501297A Expired - Fee Related JP6525432B2 (ja) | 2013-03-14 | 2014-03-11 | 抗rankl抗体および使用方法 |
| JP2018142624A Pending JP2018183176A (ja) | 2013-03-14 | 2018-07-30 | 抗rankl抗体および使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018142624A Pending JP2018183176A (ja) | 2013-03-14 | 2018-07-30 | 抗rankl抗体および使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10259878B2 (enExample) |
| EP (1) | EP2970462A4 (enExample) |
| JP (2) | JP6525432B2 (enExample) |
| CN (1) | CN105189551B (enExample) |
| HK (1) | HK1216754A1 (enExample) |
| WO (1) | WO2014159430A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014159430A1 (en) | 2013-03-14 | 2014-10-02 | Apexigen, Inc. | Anti-rankl antibodies and methods of use |
| EP3497393A4 (en) | 2016-08-08 | 2020-03-18 | Ticona LLC | Thermally conductive polymer composition for a heat sink |
| MX2019004862A (es) | 2016-10-28 | 2019-08-12 | Lilly Co Eli | Anticuerpos anti-rankl y usos de los mismos. |
| CN116041513A (zh) * | 2017-10-27 | 2023-05-02 | 河北药明生物技术有限公司 | 靶向rankl的治疗性抗体 |
| JP2022514215A (ja) * | 2018-12-05 | 2022-02-10 | ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ | Rankアンタゴニストおよびその使用 |
| TW202306990A (zh) * | 2021-05-12 | 2023-02-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 特異性結合rankl和ngf的抗原結合分子及其醫藥用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5675063A (en) | 1995-02-28 | 1997-10-07 | Loyola University Of Chicago | Immortalized rabbit hybridoma fusion partner |
| WO2002015846A2 (en) * | 2000-08-21 | 2002-02-28 | Smithkline Beecham Corporation | Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders |
| EP1432438A2 (en) * | 2001-06-06 | 2004-06-30 | Immunex Corporation | Use of rank antagonists to treat cancer |
| US7462697B2 (en) | 2004-11-08 | 2008-12-09 | Epitomics, Inc. | Methods for antibody engineering |
| US7429487B2 (en) | 2005-07-05 | 2008-09-30 | Epitomics, Inc. | Fusion partner for production of monoclonal rabbit antibodies |
| WO2008088594A2 (en) | 2007-01-12 | 2008-07-24 | Anaptysbio, Inc. | Isolation of antibodies that cross-react and neutralize rankl orginating from multiple species |
| CN101796072B (zh) * | 2007-05-24 | 2014-09-24 | 埃博灵克斯股份有限公司 | 用于治疗骨疾病和病症的针对rank-l的氨基酸序列以及包括其的多肽 |
| WO2011017294A1 (en) * | 2009-08-07 | 2011-02-10 | Schering Corporation | Human anti-rankl antibodies |
| WO2014159430A1 (en) | 2013-03-14 | 2014-10-02 | Apexigen, Inc. | Anti-rankl antibodies and methods of use |
| WO2015125922A1 (ja) | 2014-02-20 | 2015-08-27 | 国立大学法人東京大学 | 抗rankl抗体 |
-
2014
- 2014-03-11 WO PCT/US2014/023623 patent/WO2014159430A1/en not_active Ceased
- 2014-03-11 CN CN201480025695.7A patent/CN105189551B/zh not_active Expired - Fee Related
- 2014-03-11 JP JP2016501297A patent/JP6525432B2/ja not_active Expired - Fee Related
- 2014-03-11 EP EP14775208.3A patent/EP2970462A4/en not_active Withdrawn
- 2014-03-11 US US14/776,248 patent/US10259878B2/en active Active
- 2014-03-11 HK HK16104509.8A patent/HK1216754A1/zh unknown
-
2018
- 2018-07-30 JP JP2018142624A patent/JP2018183176A/ja active Pending
-
2019
- 2019-02-27 US US16/287,963 patent/US20190309080A1/en not_active Abandoned